Skip to main content
MENU

Amolyt Presented a released on "Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States" at the NEXAN Igniting Action 2021 conference in Denver.

There has been a shipment delay of NATPARA 75mcg. Patients will be receiving alternate prescriptions, temporarily. They will revert back to their original prescription once available.

Explanation from Takeda on supply disruption

The screening process to enable new participants in the clinical trial for the PTH hormone replacement, TransCon, has ended.

Amolyt Pharma will be presenting three abstracts at the 23rd European Congress of Endocrinology (e-ECE) 2021.

The conference will take place October 22-24, 2021.

On April 26, 2021, leaders from Takeda’s US Medical Affairs, Research & Development (R&D) and US Commercial organizations hosted a video teleconference with the US hypoparathyroidism community.

The HypoPARA Association and the FDA just finished their listening session and it was Amazing!

More information on SUP supply and recall status

We are incredibly excited to share that Calcilytix, a Bridgebio Company, announced early results from an ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Check out the Pathway Trial and see if you are eligible. Both short-term symptoms and long-term complications of HypoPara are addressed with TransCon PTH.

The Rare-Cap program will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.

Entera Bio announced the publication of the results of its previously completed Phase 2a study of EB612 (oral PTH) in the Journal of Bone and Mineral Research.

EveryLife Foundation releases study of estimated economic cost of 379 rare diseases.

Potential short‐term supply interruption for some patients receiving NATPARA 75‐mcg or NATPARA 100‐mcg through the Special Use Program (SUP).


REMEMBER
This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.